CALGARY, Alberta, April 23, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a biotechnology company developing novel therapies for autism spectrum disorder, related neurological and neurodevelopmental disorders, today announces it will participate in the 2nd Neuroscience Innovation Partnering & Licensing Summit on April 28-29th at the Revere Hotel Boston Common 200 Stuart St, in ...